BAMA TEA (06980) plans to buy back no more than 250 million H shares.
Ba Ma Tea Industry (06980) announces that, according to the special resolution passed by the company's shareholders at the annual general meeting held on April 21, 2026, the board of directors has been granted general authority to repurchase up to 5.2987 million of the company's H shares, equivalent to 10% of the total number of H shares issued on the day of the annual general meeting (excluding treasury shares).
BAMA TEA (06980) announced that, in accordance with the special resolution passed by the company's shareholders at the annual general meeting held on April 21, 2026, the board of directors has been granted a general mandate to repurchase up to 5.2987 million H shares of the company, representing 10% of the total number of H shares issued on the date of the annual general meeting (excluding treasury shares).
During the period of the H share repurchase mandate, the company plans to exercise the H share repurchase authorization in appropriate market conditions and from time to time repurchase the company's issued H shares on the open market, with a total repurchase amount not exceeding RMB 250 million (or the equivalent in HKD).
The company currently has a healthy cash flow and stable overall financial condition to support the continuous development of its business. The board believes that the value of the H shares traded on the market is undervalued, and the proposed H share repurchase can demonstrate the company's confidence in its business prospects and outlook, enhance returns to shareholders, ultimately benefiting the company and creating value for shareholders, aligning with the overall interests of the company and its shareholders.
Related Articles

CHINA EDU GROUP (00839) fully repaid the 5 billion yuan bonds maturing in 2026.

On April 21st, CF PHARMTECH (02652) spent HK$299,700 to repurchase 13,500 shares.

AK Medical spent HKD 4.224 million to repurchase 640,000 shares on April 21st.
CHINA EDU GROUP (00839) fully repaid the 5 billion yuan bonds maturing in 2026.

On April 21st, CF PHARMTECH (02652) spent HK$299,700 to repurchase 13,500 shares.

AK Medical spent HKD 4.224 million to repurchase 640,000 shares on April 21st.

RECOMMEND

Hong Kong Hard‑Tech Companies Enhance Canton Fair Presence As Veterans And Newcomers Expand International Networks
17/04/2026

Thousand‑Fold Oversubscription In Hong Kong IPOs Signals Multiple Market Shifts
17/04/2026

Rising Compute Costs Drive Industry Price Increases As Institutions Expect Internet Firms To Outperform In Q1
17/04/2026


